skip to content

Clinical Neurosciences

 
Read more at: First Parkinson’s patient treated in landmark phase 2 trial of Dapansutrile

First Parkinson’s patient treated in landmark phase 2 trial of Dapansutrile

26 March 2026

The first participant on the Cure Parkinson’s and Van Andel Institute co-funded trial of dapansutrile, an anti-inflammatory drug, has now received either the treatment or placebo, marking the beginning of the trial. Dapansutrile for Parkinson’s (DAPA-PD) is a clinical trial being led by Dr Caroline Williams-Gray at the...


Read more at: Study highlights stroke risk linked to recreational drugs, including among young users

Study highlights stroke risk linked to recreational drugs, including among young users

10 March 2026

The recreational drugs cannabis, cocaine and amphetamines significantly increase the risk of stroke – including among younger users – Cambridge researchers have concluded after analysing data from more than 100 million people. Stroke is a major global health challenge – the third leading cause of death and disability...


Read more at: Alzheimer’s Research UK honours Dr Maura Malpetti with 2026 early‑career award
Maura Malpetti wins an ARUK award

Alzheimer’s Research UK honours Dr Maura Malpetti with 2026 early‑career award

5 March 2026

Each year, the David Hague Early-Career Investigator of the Year award celebrates a rising star whose work is pushing the boundaries of dementia research. An external panel of distinguished researchers selects the winner, looking for scientific rigour, originality, and a clear, positive impact in the dementia research...


Read more at: New research shows how mammals shifted from night to day
A mouse outside in the day

New research shows how mammals shifted from night to day

2 March 2026

A new study has shed light on how early mammals evolved the ability to thrive in the daytime. Researchers led by Andrew Beale at the MRC Laboratory of Molecular Biology uncovered a cellular ‘switch’ that may explain how animals with fundamentally similar internal clocks can switch from nocturnal to diurnal activity...


Read more at: Neuroscience spotlight: PhD student Ellen Marie Sheridan
Ellen Sheridan

Neuroscience spotlight: PhD student Ellen Marie Sheridan

24 February 2026

Clinical Neurosciences is one of the largest and most diverse departments for clinical study at Cambridge. This week we have a chat with PhD student Ellen Marie Sheridan. She studies with us at: the NIHR HealthTech Research Centre in Brain Injury. Exploring: Rapid tests for brain tumours during operations. Her supervisor...


Read more at: The world's first study starts for brain-cooling collar

The world's first study starts for brain-cooling collar

4 February 2026

The world’s first study to measure the effectiveness of a pioneering medical device to treat patients with traumatic head injuries will get underway at Addenbrooke’s Hospital this month (Feb). The Neurosciences and Trauma Critical Care team will work with patients to trial a selective brain-cooling collar, which is applied...


Read more at: Luca Peruzzotti-Jametti joins Stem Cell Reports as an Early Career Editor 

Luca Peruzzotti-Jametti joins Stem Cell Reports as an Early Career Editor 

3 February 2026

Stem Cell Reports , the peer-reviewed, open-access journal of the International Society for Stem Cell Research (ISSCR), announced the appointment of two new Early Career Editors – Dr Bo Shen, Principal Investigator at the National Institute of Biological Sciences, Beijing (NIBS); and Dr Luca Peruzzotti-Jametti,  Clinical...


Read more at: ‘Revoice’ device gives stroke patients their voice back

‘Revoice’ device gives stroke patients their voice back

21 January 2026

Researchers have developed a wearable, comfortable and washable device called Revoice that could help people regain the ability to communicate naturally and fluently following a stroke, without the need for invasive brain implants. Read the paper: ‘ Wearable intelligent throat enables natural speech in stroke patients with...


Read more at: Immunosuppressant trial for Parkinson’s shows promising results and reveals new pathways for research

Immunosuppressant trial for Parkinson’s shows promising results and reveals new pathways for research

7 January 2026

A new study from Cambridge University has shown that an immunosuppressant treatment improved movement symptoms in Parkinson’s patients, opening up new possibilities for future research. Results from AZA-PD, a proof-of-concept trial investigating immunosuppression as a new treatment approach for Parkinson's disease, have...


Read more at: Cutting-edge baby brain scan technology is world first
•	The tiny brain imaging cap with some of the associated technology behind.

Cutting-edge baby brain scan technology is world first

7 November 2025

A team effort to develop the world’s first cot-side functional neuroimaging technology to speedily detect brain injuries including cerebral palsy in newborn babies is being spearheaded in Cambridge. The three-year Fast UltraSound Imaging with Optics in the Newborn (fUSiON) study, involving high-risk infants, is due to...